Articles by Rita Peters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Rita Peters

Rita Peters

Editorial Director

Articles
API Developers Note Upgrades, Successful Inspections
September 29, 2014

Added manufacturing capabilities, partnerships, and regulatory milestones mark recent achievements by API developers.

Excipient Variability: Causes, Identification, Control
September 29, 2014

Industry experts examine reasons why the quality and composition of excipients can vary including environmental factors, processing methods, raw material quality, manufacturing location changes, and operator actions.

Meeting the Challenges of Excipient Variability
September 1, 2014

The quality and composition of excipients can vary due to environmental factors, processing methods, raw material quality, manufacturing location changes, and even operator actions.

API Developers Pass Inspections and Upgrade Capabilities
September 1, 2014

API development and manufacturing companies expanded their capabilities, built partnerships, and achieved milestones in regulatory inspections.

Contract Providers Assume Expanded Responsibilities
September 1, 2014

Contract service providers are playing a more diverse role in drug development.

A Silver Milestone for Drug Development
August 2, 2014

Pharmaceutical Technology Europe marks 25 years of drug-development advances.

Shifting Gears in Drug Development Outsourcing Responsibilities
August 1, 2014

For a bio/pharma industry in flux, contract services are playing a greater—and more diverse—role in drug development.

Benefits and Risks of Drug Information on Social Media
July 2, 2014

FDA draft guidances seek to maintain accurate drug information for patients in new media.

Biopharma Takes a Nervous Glance Over Its Shoulder
May 2, 2014

Changes are needed to maintain US biopharma innovation leadership.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here